Harmony Biosciences

Harmony Biosciences Secures FDA Orphan Drug Designation for Pitolisant in Prader-Willi Syndrome Treatment

PLYMOUTH MEETING, PA — The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Harmony Biosciences Holdings, Inc.’s (Nasdaq: HRMY) pitolisant for the treatment of Prader-Willi syndrome …

Harmony Biosciences Secures FDA Orphan Drug Designation for Pitolisant in Prader-Willi Syndrome Treatment Read More

Larimar Therapeutics

Pioneering Leap for Friedreich’s Ataxia Treatment: Larimar Therapeutics Announces Encouraging Phase 2 Results for Nomlabofusp

BALA CYNWYD, PA — The clinical-stage biotech firm Larimar Therapeutics has reported promising top-line data from its Phase 2 dose exploration study. The groundbreaking study tested the medication ‘nomlabofusp’ on …

Pioneering Leap for Friedreich’s Ataxia Treatment: Larimar Therapeutics Announces Encouraging Phase 2 Results for Nomlabofusp Read More